IMCLONE'S ERBITUX APPROVED IN CANADA FOR COLON CANCER

ImClone Systems Inc. and Bristol-Myers Squibb Co. said their Erbitux treatment for colon cancer has been approved for sale in Canada. Erbitux, a new type of drug that blocks cancer growth with fewer side effects than standard chemotherapy, was approved as a second-line treatment for when initial therapy fails to stop the spreading cancer. It is given either with Pfizer Inc.'s Camptosar or alone in patients who can't take the older cancer drug, the New York-based companies said today in a statement.

Bloomberg.com (http://www.bloomberg.com/apps/news?pid=10000082&sid=aXikXbPPrgeU&refer=canada)